Sharlene Adams

2.4k total citations · 1 hit paper
44 papers, 2.0k citations indexed

About

Sharlene Adams is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Sharlene Adams has authored 44 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Molecular Biology. Recurrent topics in Sharlene Adams's work include Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (10 papers) and Glycosylation and Glycoproteins Research (6 papers). Sharlene Adams is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (10 papers) and Glycosylation and Glycoproteins Research (6 papers). Sharlene Adams collaborates with scholars based in United States, Australia and Japan. Sharlene Adams's co-authors include Somnath Datta, Chandra Mohan, Barry Jones, Michael I. Jesson, Glenn T. Miller, Barbara Wallner, Takeshi Watanabe, Robert E. Humphreys, Syamal K. Datta and Pierre Leblanc and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Sharlene Adams

44 papers receiving 1.9k citations

Hit Papers

Nucleosome: a major immun... 1993 2026 2004 2015 1993 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus.
    1993 527 citations Chandra Mohan, Sharlene Adams et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sharlene Adams United States 16 998 747 641 525 492 44 2.0k
Jean‐Louis Pasquali France 25 1.3k 1.3× 240 0.3× 541 0.8× 358 0.7× 750 1.5× 58 2.3k
Liliane Fossati‐Jimack United Kingdom 27 1.6k 1.6× 169 0.2× 365 0.6× 448 0.9× 444 0.9× 65 2.1k
Kirsten A. Fairfax Australia 21 1.6k 1.6× 352 0.5× 268 0.4× 837 1.6× 244 0.5× 34 2.6k
Marion Espéli France 21 1.0k 1.0× 395 0.5× 152 0.2× 484 0.9× 198 0.4× 50 1.6k
Silke Meister Germany 16 889 0.9× 231 0.3× 162 0.3× 630 1.2× 297 0.6× 26 1.8k
Susan A. Boackle United States 18 1.3k 1.3× 154 0.2× 395 0.6× 271 0.5× 571 1.2× 37 1.8k
Erik R Vossenaar Netherlands 16 584 0.6× 399 0.5× 920 1.4× 724 1.4× 1.6k 3.2× 16 2.7k
Josef Borvák United States 7 1.3k 1.3× 315 0.4× 378 0.6× 430 0.8× 961 2.0× 12 1.8k
Atsuo Nakajima Japan 19 1.1k 1.1× 445 0.6× 178 0.3× 383 0.7× 407 0.8× 34 1.8k
Mohammad Zafari United States 16 1.5k 1.5× 348 0.5× 323 0.5× 506 1.0× 255 0.5× 29 2.0k

Countries citing papers authored by Sharlene Adams

Since Specialization
Citations

This map shows the geographic impact of Sharlene Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharlene Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharlene Adams more than expected).

Fields of papers citing papers by Sharlene Adams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharlene Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharlene Adams. The network helps show where Sharlene Adams may publish in the future.

Co-authorship network of co-authors of Sharlene Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Sharlene Adams. A scholar is included among the top collaborators of Sharlene Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharlene Adams. Sharlene Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pace, Emily A., Sharlene Adams, Michael D. Curley, et al.. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research. 24(12). 2873–2885. 44 indexed citations
3.
Kovtun, Yelena, Gregory E. Jones, Sharlene Adams, et al.. (2018). A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances. 2(8). 848–858. 129 indexed citations
4.
5.
Fitzgerald, Jonathan B., Bryan W. Johnson, Jason Baum, et al.. (2013). MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors. Molecular Cancer Therapeutics. 13(2). 410–425. 87 indexed citations
6.
McDonagh, Charlotte F., Alexandra Huhalov, Brian D. Harms, et al.. (2012). Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3. Molecular Cancer Therapeutics. 11(3). 582–593. 222 indexed citations
7.
Baum, Jason, Bryan W. Johnson, Sharlene Adams, et al.. (2012). Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity. Cancer Research. 72(8_Supplement). 2719–2719. 3 indexed citations
8.
Lugovskoy, Alexey A., Bryan W. Johnson, Jason Baum, et al.. (2011). Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.. Molecular Cancer Therapeutics. 10(11_Supplement). B205–B205. 2 indexed citations
9.
Jesson, Michael I., Paul A. McLean, Glenn T. Miller, et al.. (2007). Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent. Cancer Research. 67. 1894–1894. 6 indexed citations
10.
Jones, Barry & Sharlene Adams. (2006). Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100). Cancer Research. 66. 1094–1094. 3 indexed citations
11.
Adams, Sharlene & Barry Jones. (2004). Enhanced anti-tumor activity of dipeptidyl peptidase inhibitor PT-100 in combination with chemotherapy in mice.. Cancer Research. 64. 882–882. 1 indexed citations
12.
Adams, Sharlene, et al.. (2003). Perianal Hodgkin's lymphoma complicating Crohn's disease. International Journal of Colorectal Disease. 18(2). 174–176. 6 indexed citations
13.
Humphreys, Robert E., et al.. (2000). Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine. 18(24). 2693–2697. 60 indexed citations
14.
Adams, Sharlene, Fernando Alberício, Jordi Alsina, Edwin R. Smith, & Robert E. Humphreys. (1997). Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules.. PubMed. 47(9). 1069–77. 21 indexed citations
15.
Adams, Sharlene & Robert E. Humphreys. (1995). Invriant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. European Journal of Immunology. 25(6). 1693–1702. 38 indexed citations
16.
Mohan, Chandra, et al.. (1993). Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus.. The Journal of Experimental Medicine. 177(5). 1367–1381. 527 indexed citations breakdown →
17.
18.
Vlahakos, Demetrios, Mary H. Foster, Sharlene Adams, et al.. (1992). Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney International. 41(6). 1690–1700. 170 indexed citations
19.
Adams, Sharlene, et al.. (1990). T cell receptor Vβ genes expressed by IgG anti‐DNA autoantibody‐inducing T cells in lupus nephritis: Forbidden receptors and double‐negative T cells. European Journal of Immunology. 20(7). 1435–1443. 29 indexed citations
20.
Pons, Héctor, Sharlene Adams, & Miguel J. Stadecker. (1988). Schistosoma mansoni: The basis for the antischistosomal effect of cyclosporine A. Experimental Parasitology. 67(2). 190–198. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Louis Pasquali Breakdown of academic impact, for papers by Liliane Fossati‐Jimack Breakdown of academic impact, for papers by Kirsten A. Fairfax Breakdown of academic impact, for papers by Marion Espéli Breakdown of academic impact, for papers by Silke Meister Breakdown of academic impact, for papers by Susan A. Boackle Breakdown of academic impact, for papers by Erik R Vossenaar Breakdown of academic impact, for papers by Josef Borvák Breakdown of academic impact, for papers by Atsuo Nakajima Breakdown of academic impact, for papers by Mohammad Zafari
Rankless by CCL
2026